Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DENO49
|
|||
| Drug Name |
RV521
|
|||
| Synonyms |
RV521 free base; UNII-KE63TTO7WK; KE63TTO7WK; RV-521; 1903763-82-5 (free base); 1'-((5-(aminomethyl)-1-(4,4,4-trifluorobutyl)-1H-benzo[d]imidazol-2-yl)methyl)-6'-fluorospiro[cyclopropane-1,3'-indolin]-2'-one; 1903763-82-5; Sisunatovir; CHEMBL4297497; SCHEMBL19470916; EX-A4653; RV 521; NCC1=CC2=C(N(C(=N2)CN2C(C3(C4=CC=C(C=C24)F)CC3)=O)CCCC(F)(F)F)C=C1; 1'-{[5-(aminomethyl)-1-(4,4,4-trifluorobutyl)-1H-benzimidazol-2-yl]methyl}-6'-fluorospiro[cyclopropane-1,3'-indol]-2'(1'H)-one; Spiro(cyclopropane-1,3'-(3H)indol)-2'(1'H)-one, 1'-((5-(aminomethyl)-1-(4,4,4-trifluorobutyl)-1H-benzimidazol-2-yl)methyl)-6'-fluoro-; WVA
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Respiratory syncytial virus infection [ICD-11: 1C80; ICD-9: 79.6] | Phase 2 | [1] | |
| Company |
ReViral
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C23H22F4N4O
|
|||
| Canonical SMILES |
C1CC12C3=C(C=C(C=C3)F)N(C2=O)CC4=NC5=C(N4CCCC(F)(F)F)C=CC(=C5)CN
|
|||
| InChI |
1S/C23H22F4N4O/c24-15-3-4-16-19(11-15)31(21(32)22(16)7-8-22)13-20-29-17-10-14(12-28)2-5-18(17)30(20)9-1-6-23(25,26)27/h2-5,10-11H,1,6-9,12-13,28H2
|
|||
| InChIKey |
JOPCJJSYRPUEDS-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 1903763-82-5
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Respiratory syncytial virus protein F (RSV F) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03258502) Safety, Pharmacokinetics and Antiviral Activity of RV521 Against RSV. U.S. National Institutes of Health. | |||
| REF 2 | Discovery of Sisunatovir (RV521), an Inhibitor of Respiratory Syncytial Virus Fusion. J Med Chem. 2021 Apr 8;64(7):3658-3676. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.